Institutional Investor Sentiment About Tax Exempt Securities Trust Series 289 (NYSE:CBM) Increased

Sentiment for Tax Exempt Securities Trust Series 289 (NYSE:CBM)

Tax Exempt Securities Trust Series 289 (NYSE:CBM) institutional sentiment increased to 1.51 in Q2 2018. Its up 0.32, from 1.19 in 2018Q1. The ratio has increased, as 124 investment professionals started new or increased holdings, while 82 reduced and sold their equity positions in Tax Exempt Securities Trust Series 289. The investment professionals in our partner’s database now possess: 32.93 million shares, up from 32.42 million shares in 2018Q1. Also, the number of investment professionals holding Tax Exempt Securities Trust Series 289 in their top 10 holdings decreased from 1 to 0 for a decrease of 1. Sold All: 31 Reduced: 51 Increased: 87 New Position: 37.

Cambrex Corporation, a life sciences company, provides various services and products for the development and commercialization of new and generic therapeutics worldwide. The company has market cap of $1.55 billion. The companyÂ’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. It has a 11.79 P/E ratio. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics.

The stock decreased 2.56% or $1.21 during the last trading session, reaching $46.06. About 26,926 shares traded. Cambrex Corporation (NYSE:CBM) has risen 30.46% since December 6, 2017 and is uptrending. It has outperformed by 14.84% the S&P500.

Analysts await Cambrex Corporation (NYSE:CBM) to report earnings on February, 14. They expect $1.32 earnings per share, up 3.94 % or $0.05 from last year’s $1.27 per share. CBM’s profit will be $44.31 million for 8.72 P/E if the $1.32 EPS becomes a reality. After $0.79 actual earnings per share reported by Cambrex Corporation for the previous quarter, Wall Street now forecasts 67.09 % EPS growth.

Ranger Investment Management L.P. holds 2.55% of its portfolio in Cambrex Corporation for 697,689 shares. American Capital Management Inc owns 720,476 shares or 1.95% of their US portfolio. Moreover, Summit Creek Advisors Llc has 1.45% invested in the company for 154,231 shares. The Massachusetts-based Portolan Capital Management Llc has invested 1.22% in the stock. Investment Counselors Of Maryland Llc, a Maryland-based fund reported 464,112 shares.

Since January 1, 0001, it had 0 buys, and 5 sales for $10.70 million activity.

More notable recent Cambrex Corporation (NYSE:CBM) news were published by: Globenewswire.com which released: “Cambrex Completes Acquisition of Halo Pharma NYSE:CBM – GlobeNewswire” on September 12, 2018, also Streetinsider.com with their article: “Cambrex Corporation (CBM) PT Lowered to $60 at Stephens Following 3Q – StreetInsider.com” published on November 12, 2018, Fool.com published: “Cambrex Corp (CBM) Q3 2018 Earnings Conference Call Transcript – Motley Fool” on November 08, 2018. More interesting news about Cambrex Corporation (NYSE:CBM) were released by: Globenewswire.com and their article: “Cambrex Reports Second Quarter 2018 Financial Results NYSE:CBM – GlobeNewswire” published on August 02, 2018 as well as Seekingalpha.com‘s news article titled: “Follow-Up Analysis Supporting Cambrex Short Thesis – Seeking Alpha” with publication date: October 16, 2018.

Cambrex Corporation (NYSE:CBM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.